theMednetRegister

Rheumatology

CTD-ILD   

Questions discussed in this category

How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Is this managed as CTD-ILD with immunosuppressive +/- anti-fibrotic agents?
1 Answer available
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
1 Answer available
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
1 Answer available
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
CT changes are subsolid and ground glass nodules.
1 Answer available
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA
1 Answer available
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
Do you ever start mycophenolate without steroids?
1 Answer available
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
Given poor pulmonary outcomes in people with anti-PL12 antibodies, would you recommend more aggressive therapy? The patient was diagnosed with onset o...
1 Answer available
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
3 Answers available
How would you approach treatment of active inflammatory arthritis in a patient with MCTD (+RNP/+Chromatin) and stable ILD who has failed MMF, azathioprine and methotrexate?
Would you consider belimumab over a TNF inhibitor for inflammatory arthritis? Which agent would be more beneficial for the lung disease?
2 Answers available
What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?
2 Answers available


Papers discussed in this category

The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Respirology, 2013 Nov 29
Rituximab in severe, treatment-refractory interstitial lung disease.
Respir Res, 2022 Jun 21
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
Arthritis & rheumatology (Hoboken, N.J.), 2015-05
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
International journal of rheumatic diseases, 2014-02
Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Clinical nuclear medicine, 2016-05
FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.
J Investig Med High Impact Case Rep, 2021 Jan-Dec
Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.
Clinical therapeutics, 2018 Feb
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Seminars in arthritis and rheumatism, 2018 Jan 06
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
Lancet Respir Med, 2023 Jan
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Rheumatology (Oxford, England), 2021 Dec 24
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
Current opinion in pulmonary medicine, 2023 Jun 30
Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.
Rheumatology (Oxford, England), 2023 Feb 01
Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Rheumatology (Oxford),
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
Rheumatology (Oxford, England), 2023 Dec 01
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.